Orlistat for obesity benefits beyond weht loss. - NCBI ) is used as an adjunct to caloric restriction, increased physical activity, and behavioral modification in the treatment of exogenous obesity; also used to reduce the risk of weht regain after initial loss. Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. Orlistat lowers lipids and improves insulin sensitivity, but its effect on other metabolic syndrome related. PMID 15620437; PubMed - indexed for MEDLINE.
Orlistat use in type 2 diabetes. - NCBI In August 2009, FDA reported that it was conducting an ongoing safety review of orlistat prompted by reports of adverse hepatic-related effects (e.g., serious hepatic injury requiring hospitalization, liver failure) in patients receiving the drug. OBJECTIVE To review the use of orlistat in type 2 diabetes. DATA SOURCES A MEDLINE search of the. PMID 12086556; PubMed - indexed for MEDLINE.
Effect of orlistat on cardiovascular disease risk in obese adults. - NCBI It prevents the absorption of dietary fat by inhibiting the key enzymes needed for converting dietary fat to its absorbable form. AIM The aim of this study is to compare the effect of orlistat vs. placebo on the predicted 10-year. PMID 15811142; PubMed - indexed for MEDLINE.
Rating: 95 / 100
Overall: 93 Rates